Hutchmed registers Phase III trial of HMPL-306 in IDH-mutant grade 2 glioma
The randomized, placebo-controlled study was listed on clinicaltrials.gov with a status of not yet recruiting and an estimated enrollment of 210 participants.
Hutchmed's registry activity for the week centers on a single new Phase III glioma study.
- HMPL-306, an oral tablet, is being tested in a Phase III trial for postoperative residual or recurrent grade 2 glioma harboring IDH1 or IDH2 mutations1. The trial is listed as not yet recruiting, with an estimated start date of 2026-11 and plans to enroll approximately 210 participants with postoperative residual or recurrent grade 2 astrocytoma or oligodendroglioma carrying IDH1 or IDH2 mutations who have previously received only surgical treatment1. The primary endpoint is PFS assessed by BIRC according to Response Assessment in Neuro-Oncology (RANO) 2.0 criteria, measured up to approximately 30 months1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.